Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 11/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27983377 | 1.00 | FPR2 (0.64) | FPR2ALDH1A1MEN1KMT2ANAALAD2 | |
| SCHEMBL14948976 | 0.92 | FPR2 (0.58) | FPR2ALDH1A1MEN1KMT2AALOX15 | |
| SCHEMBL14937925 | 0.85 | FPR2 (0.65) | FPR2ALDH1A1MEN1KMT2AALOX15 | |
| SCHEMBL14937668 | 0.85 | FPR2 (0.65) | FPR2ALDH1A1MEN1KMT2AALOX15 | |
| SCHEMBL14937629 | 0.85 | FPR2 (0.64) | FPR2ALDH1A1MEN1KMT2ANAALAD2 | |
| SCHEMBL14948928 | 0.84 | NLRP3 (0.49) | FPR2KMT2A | |
| SCHEMBL18191809 | 0.80 | FPR2 (0.45) | FPR2ALDH1A1NAALAD2 | |
| SCHEMBL6380805 | 0.79 | FPR2 (1.00) | FPR2 | |
| SCHEMBL6376031 | 0.79 | FPR2 (1.00) | FPR2 | |
| SCHEMBL6376040 | 0.79 | FPR2 (1.00) | FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3088385-A1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-11-02 | — | — | EP | claimed |
| EP-2776389-B1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2016-09-21 | — | — | EP | claimed |
| CN-104169254-A | Aryl urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators | ALLERGAN INC | 2014-11-26 | — | — | CN | claimed |
| EP-2776389-A1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| US-8816076-B2 | Aryl urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators | ALLERGAN, INC. (US) | 2014-08-26 | — | — | US | claimed |
| US-20130331570-A1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-12-12 | — | — | US | claimed |
| WO-2013070600-A1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | WO | claimed |
| US-20130123496-A1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTORS LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | claimed |
| EP-3088385-A1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-3088385-A1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2776389-B1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2016-09-21 | — | — | EP | disclosed |
| CN-104169254-A | Aryl urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators | ALLERGAN INC | 2014-11-26 | — | — | CN | disclosed |
| EP-2776389-A1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-09-17 | — | — | EP | disclosed |
| US-8816076-B2 | Aryl urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators | ALLERGAN, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130331570-A1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| US-8541577-B2 | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators | ALLERGAN, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541577-B2 | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators | ALLERGAN, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| WO-2013070600-A1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130123496-A1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTORS LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2013070600-A1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331570-A1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | FPR1, FPR3, FPR2 | FPR2 3/4885ALDH1A1 3917/4885MEN1 4565/4885 |
| US-20130123496-A1 | ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTORS LIKE-1 (FPRL-1) RECEPTOR MODULATORS | FPR1, FPR3, FPR2 | FPR2 3/4885ALDH1A1 3881/4885MEN1 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.